Skip to main
ARDX

Ardelyx (ARDX) Stock Forecast & Price Target

Ardelyx (ARDX) Analyst Ratings

Based on 8 analyst ratings
Strong Buy
Strong Buy 63%
Buy 38%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ardelyx is well-positioned in the biopharmaceutical industry with a promising drug pipeline, strong financial projections, and a potential blockbuster drug in Ibsrela. With positive results from clinical trials and a strong patent portfolio, the company has the potential for significant growth and could become a major player in the market. The future success of Ibsrela and Xphozah will be key drivers of Ardelyx's growth, making it an attractive investment option for those with a long-term view.

Bears say

Ardelyx is facing challenges in achieving its revenue goals for Ibsrela and Xphozah, with only moderate increases in R&D and SG&A expenses predicted for FY26 and its target price remaining unchanged at $19. Despite being the only sodium transport inhibitor in two approved indications, the drug faces significant competition and pricing pressures in a complex and price-sensitive commercial market. Additionally, there is still considerable unmet need in both target diseases, suggesting a lack of widespread demand or success for the drug.

Ardelyx (ARDX) has been analyzed by 8 analysts, with a consensus rating of Strong Buy. 63% of analysts recommend a Strong Buy, 38% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ardelyx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ardelyx (ARDX) Forecast

Analysts have given Ardelyx (ARDX) a Strong Buy based on their latest research and market trends.

According to 8 analysts, Ardelyx (ARDX) has a Strong Buy consensus rating as of Aug 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ardelyx (ARDX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.